

2023年环境、社会及[illegible]告报告

上海复宏汉[illegible]份有限[illegible]

ha[illegible]i Henlius Bio



About This Report
Management Message
The Value We Created
Company Overview



This is the ýfth Environmental, Social and Governance ("ESG report") published by Shanghai Henlius Biotech, Inc. ("Henlius", "We" or "the Company"). The purpose of this report is to provide shareholders, employees, the government, customers, partners, media, public and other stakeholders

Basis and Reference

Governance (ESG) Reporting Guide of Rules Governing the Listing of Securities on the Stock Exchange of Hong Kong Limited

Related Listing Rules released by The Stock Exchange of Hong Kong Limited. The compilation of the report follows and aligns with

Company from 1 January 2023 to 31 December 2023 (the "Reporting Period" or the "current year"), the same as that of the 2023 Annual

This report covers Shanghai Henlius Biotech, Inc. (2696.HK) and

Report; and the ýnancial data involved are consistent with the 2023

unless otherwise speciýed. Other data and cases mainly come from

Report Veriýcation

the Global Reporting Initiative standards (GRI standards) and the AA1000 series of standards. The scope of veriýcation of this report is the ofýce area and manufacturing facilities in Xuhui and Songjiang,

and English versions, the Simpliýed Chinese version shall prevail.

(_____) and the ofýcial website of Henlius (_____).

In 2023, Henlius adhered to the concept of "patient-centricity", navigated patients, bearing the mission of "to improve patients' lives by timely providing them with quality and affordable protein therapeutics", and has successfully launched 5 self-developed products, beneýting over 580,000 patients, and have Brazil. Our core product, HANQUYOU (trastuzumab), has been approved for HANSIZHUANG (serplulimab), the world's ýrst anti-PD-1 mAb approved for the ýrst-line treatment of small cell lung cancer (SCLC), has been approved for 4 indications in China and also launched in Indonesia, becoming the ýrst China-quality, beneýting a broader global patient population.

Product

Marketed Products

5
2

Patients Benefited

580,000+

Product Access

4

HANQUYOU:

HANSIZHUANG:

medical insurance (Huiminbao).

Moleculars in R&D

50+

R&D Investment

1.4336

Product Designation

HANSIZHUANG

HLX208 (an innovative BRAF small-molecule inhibitor) granted a Breakthrough Therapy Designation by the NMPA for mutated adult Langerhans cell histiocytosis and Erdheim-Chester disease (ECD)

Commercial Manufacturing Capacity

48,000 L

Lean Production

GMP Training

179,509.53
161

GMP Certification

Certified by China, EU, PIC/S members Indonesia and Brazil

In-house Product Testing

100%

Talent

Employee Equality

51%
19

Employee Diversity

48
110

Employee Development

77.61
2.6163

Occupational Health and Safety

44,241 12.16

Employee Care

0.3

Environment



Henlius (Stock code: 2696.HK) is a global biopharmaceutical company with the vision to offer high-quality, affordable, and innovative biologic medicines for patients worldwide with a focus on oncology, autoimmune diseases, and

the U.S., and the EU, respectively. At the end of March 2024, the Company's marketed products have beneýted over 580,000 patients. Among these products, HANLIKANG (rituximab), Henlius' ýrst product, is the ýrst China-developed biosimilar. Our core oncology product HANQUYOU (trastuzumab, trade names: Zercepac in Europe), is the ýrst China-developed mAb biosimilar approved both in China and Europe. HANSIZHUANG (serplulimab), Henlius' ýrst innovative mAb, has been approved for the treatment of microsatellite instability-high (MSI-H) solid tumors, squamous non-small cell lung cancer (sqNSCLC), extensive-stage small cell lung cancer (ES-SCLC), and esophageal squamous cell carcinoma (ES-SCLC). HANSIZHUANG is the world's ýrst anti-PD-1 mAb approved by the NMPA for the ýrst-line treatment of SCLC and mAb the Ab approved is anti PD-1 anti-PD-1 and NMPA is the SCLC treatmes



Listed

2023 Top 10 Most Inþuential Antibody Company

2023 Top 20 Chinese Pharmaceutical Listed Companies in ESG

China Listed Company Reputation Ranking "Biopharmaceutical Company with the Most Growth"

Listed Enterprises 2023

Bloomberg Businessweek (Chinese Edition)

To the Time, to Life ï cancer patient care program

2rises

(Songjiang Facility)






In the pursuit of sustainable corporate development, Henlius adheres to an ESG management strategy, considering it as a crucial part of its corporate strategy and a signiýcant driver for achieving long-term sustainability. Aligning with the evolving trends of both the Company and the industry, we updated the different modules of our strategy model in 2022, primarily focusing on ýve key areas, and have continued to implement related work in 2023. Around these modules, we have implemented targeted action measures to substantially enhance the Company's ESG performance, laying a



We practice compliant and efýcient corporate

value of putting integrity ýrst, to achieve

to improve drug access to beneýt





Henlius deeply embeds the concept of quality ýrst in the whole life cycle of products, strictly controls

R&D and innovation, and seek diversiýed innovation internally and externally, exploring more drug forms and disease areas, to ensure that the mission of "to improve patients' lives by timely providing them with quality and affordable protein therapeutics" is implemented and thus providing better

the reporting period, the Company has successfully launched ýve products in China and two



HANQUYOU

As Henlius' ýrst novel mAb, HANSIZHUANG (serplulimab) has been successively used for

since its approval in March 2022. It is the world's ýrst anti-PD-1 mAb approved for the ýrst-line treatment of small cell lung cancer, beneýting more than 60,000 patients. of Mfor

Henlius gives full play to its professional advantages in the ýeld of medicine and healthcare, intensiýes the market penetration of products in the

them with quality and affordable protein therapeutics, so that high-quality drugs can beneýt more patients from developing countries, emerging

Henlius and CR PHARMA COMM Entered Into Strategic Cooperation



business model of "healthcare + Internet" and integrate conventional

eýcient medical service system closer to patients' needs, and continuously

DTP (Direct to Patient)

Henlius Promoted Drug Access in Remote Areas in China in 2023

During the reporting period, Henlius continued to expand the access to drugs in remote areas and achieved signiýcant progress. By

Guizhou, Ningxia, Qinghai, Xinjiang, Yunnan, Tibet, among others. Among them, 84,000 units of HANQUYOU (150mg) and more than 14,000 units of HANQUYOU (60mg) were distributed to terminal users.

Henlius Works Together with KGbio to Enter Middle East and North African (MENA) Markets for HANSIZHUANG

("Kalbe"), an Indonesian pharmaceutical company, for the development and commercialisation of HANSIZHUANG as a treatment for two indications including ES-SCLC in 12 MENA

patient needs in more regions. In December 2023, HANSIZHUANG was approved in Indonesia, becoming the ýrst domestic PD-1 mAb approved in Southeast Asia.

Henlius Entered into Collaboration with Intas Pharmaceuticals Limited

In October 2023, Henlius announced collaboration with Intas Pharmaceuticals Limited ("Intas"), to which it granted the rights to conduct exclusive development and commercialization of Henlius' independently-developed HANSIZHUANG for indicatiots including ex ∧ ensive ! § elg lung cancer as welg as pesi ¸ s it eubo \ e and Indiaɔu

Henlius Continues Collaboration with Abbott for Semi-exclusive Commercial Licensing

Henlius continues to carry out commercial collaboration with Abbott Operations Uruguay S.R.L., to which it authorizes the semi-exclusive commercial rights of Henlius' two independently-developed products (HANLIKANG and HANQUYOU) in Brazil. This will not only help the Company further expand its overseas market, but also enhance the availability of these products in the local market and better meet the needs of Brazilian patients through collaboration with Abbott. In 2023, Henlius Xuhui Facility obtained GMP certiýcation for HANLIKANG and HANQUYOU from the Brazilian National Health Supervision Authority (ANVISA), a member of PIC/S. In 2024, HANQUYOU was approved in Brazil.



With a patient-centered approach, Henlius focuses on patients' unmet clinical needs, and identiýes key R&D directions. The Company makes unremitting efforts to improve the global clinical operation system. Henlius actively conducts and accelerates various clinical trials with immune-oncology combination therapies, covering a wide range of high-incidence tumors, including lung cancer and gastric cancer. Meanwhile, we continue to promote R&D innovation and product pipeline building through diversiýed innovation and open cooperation in collaboration with global innovation resources, so as to achieve multi-dimensional innovation in drugs to ýght in more disease areas. In 2023, the Company invested a total of RMB 1.4336 billion in R&D, and a total of 11 products have made new progress in research and development.

	Countries and regions where ýrst patient
HANSIZHUANG (serplulimab)	LS-SCLC
HLX04-O (VEGF)	
HLX60 (GARP) + HANSIZHUANG (serplulimab)	
HLX14 (denosumab biosimilar)	

Henlius adheres to the R&D innovation strategy of "internal innovation and external collaboration", accelerates the transformation and a wealth of drug forms, such as monoclonal antibody, bispeciýc antibody, antibody-drug conjugates (ADC), recombinant protein, small molecule

Henlius has established global innovation center that is committed to building a comprehensive and eýcient innovative drug R&D system,

the safety window, therapeutic window, selectivity and eýciency of ADC medicines and expand the application scenarios and scope of ADC products. While continuing to deepen oncology research, the center also takes proactive steps toward the non-oncology ýeld, so as to respond

reached 103 (excluding dispatched workers and interns), among whom doctors and masters accounting for 53% and 38% respectively.

Leverage external forces for innovation

At the same time, Henlius fully leverages external innovative forces for more innovative resources. In May 2023, Henlius convened the ýrst Overseas Scientiýc Advisory Board (SAB) .

tumor immunotherapy, discussed the scientiýc references, competition landscape, the latest R&D data and next step plans of the Company's early research pipeline, and proposed recommendations on the priority setting of different R&D programs, the selection of disease ýelds and the allocation of R&D resources. Henlius will continue to develop breakthrough therapies, enhance innovation and international inþuence, and beneýt more patients worldwide.

. 16 data results were presented at ýve international academic conferences. The results of phase 3 clinical trial (ASTRUM-007) of HANSIZHUANG combined chemotherapy for ýrst-line treatment of Esophageal Squamous Cell Carcinoma

*1: Granted Orphan Drug Designations by the U.S. FDA and the EU EC

*2: Included in the Catalog of Rare Diseases by the National Health Commission of China

Henlius Successfully Launched Public Service Platform



In January 2023, six projects of the "Mars Landing Program" in

embedded with quality-related workþows including deviation, changes control, corrective and preventive measures (CAPA), out of speciýcation (OOS) / out of trend (OOT), complaints, supplier management, supplier audit, internal audit and external audit. Henlius continuously

of production regulatory matters, improve work efýciency, and reduce the possibility of problems in the production link by optimizing the þuency

management systems, and proactively identiýed potential risks in the operation of quality system.


quality system maintenance, material management and other management modules were identiýed

and packaging materials for commercialization and clinical production, intermediate control testing, stock solution and ýnished product testing,

Henlius Xuhui Facility completed the launching of the Electronic Laboratory Notebook (ELN) system for two commercial products, HANBEITAI

system monitoring as well as other test records of the four launched products ð HANLIKANG, HANQUYOU, HANBEITAI ɔ o K ɨof four


In addition, we have continued to carry out quality culture activities and organized a variety of online and ofþine promotional activities. A one-week "Planet Q Roaming Program" quality culture activity was carried out by integrating such aspects as corporate mission, vision and values, quality culture, Employer Value Proposition (EVP), GMP and clinical compliance quality through a variety of online live streaming activities, quiz and ofþine interactions.



In order to ensure the quality of training, Henlius has strengthened qualiýcation certiýcation process of lecturers, built a professional lecturer team composed of Subject Matter Experts (SME) and heads from all business sectors, actively searched for high-quality external training

and handling of nonconforming products. We have established the Global Drug Safety Committee (GDSC) and the Beneýt-Risk Council (BRC), responsible for analyzing, evaluating and identifying risks related to product safety to evaluate product risks and beneýts. In the face of the identiýed risks, we will implement corresponding risk control measures tailored to the characteristics of each risk to minimize the potential


In response to the adverse event management, during the reporting period, the Company carried out training on adverse event reporting policy among all employees through online learning platform "Henlius Academy".


Audit conýrmation and notiýcation
Audit certiýcate
Auditors conýrm CAPA implementation


diversiýed talent team. We support continuous progress among employees and provide diversiýed learning resources


happiness, we provide employees with complete beneýt packages and carry out employee care activities, and pay










Contractor (the Disabled)

Henlius R&D Graduate Traineeship Program

proýciency.

Henlius and Educational Institution Yeehong Business School Reached Cooperative Training Agreement




In 2023, Henlius carried out talent review. We have veriýed key positions and capability requirements based on the development status of different businesses and future planning, evaluated the professional proýciency,

As for the HIPO (High Potential) identified, HRBP (Human Resource Business Partner) organizes them to

to the market salary level and local economic development, committed to providing employees with continuously competitive compensation and beneýts in

adhere to the integration principles of the Annual Business Goal 2023 (Business Plan), Performance Measurement Baseline (PMB), and Key Performance Indicator (KPI), further reýne our performance appraisal methods, continue to follow the three-stage full-performance appraisal cycle of goal setting, performance



Low Performance


"Blockbuster"

In 2023, Henlius reserved the previously-established R&D "Blockbuster" incentive mechanism that was open

namely "major blockbusters", "innovative blockbusters", "authoritative blockbusters" and "research blockbusters',

"blockbuster" incentive recogni tive

At Henlius, we provide our employees with wide-ranging beneýts, including monthly subsidies of various types, supplementary provident funds, provide non-salary beneýts such as additional commercial insurances for all full-time employees and their children, as well as employer liability






Henlius has established diversiýed communication platform to carefully listen to the inner voice of employees through "Leadership Face to Face"

Henlius attaches great importance to employees' grievance reporting and actively helps employees solve problems and difýculties in work


case of unsatisfactory communication, they can ýle grievance to HR department. This initiative provides a platform for employees to express

Henlius Provides Accommodation for Employees

completed resources integration of 4 talent apartments in the ýrst half of 2023.



application channels, and offer corresponding housing beneýts during their stay,



"general risk assessment of occupational hazards of employers" and "qualitative assessment of industrial health". As for general risk assessment of occupational hazards of employers, we were ýnally


Classiýed Supervision and Law Enforcement for Occupational Health



Safety Production Law of the People's Republic of China
Law of the People's Republic of China on the Prevention and Control

pregnant/breastfeeding female employees, change process, ýrst-aid

poisoning and other events, reýne the emergency management and



Henlius has always been adhering to the environmental management guidelines of "preventing environmental pollution and reducing energy consumption", integrating the concept of green development throughout our production processes, sticking to responsible production principles. In 2023, we made signiýcant efforts in energy conservation emissions, we fulýll our environmental responsibilities.

Resource Efýciency


Low-emission energy sources: use clean

on Climate-related Financial Disclosure (TCFD), and formulating contingency plans to address different risks.


implement climate risk management measures, both in terms of prevention and response. In 2023, we developed plans for þood prevention levels, and drainage paths and rescue plans are clearly deýned in the event of heavy rainfall.

Henlius Songjiang Second Plant Emergency Response to Heavy Rainfall

established a þood emergency response team and identiýed low-lying areas and potential þood-prone area at the production base, implementing warnings



Environmental Protection Law of the People's Republic of China, Law of Law of the People's Republic of China on the Prevention and Control of Water Pollution, Pollution Prevention Law of the People's Republic of China. We aim to become the ýrst class of environment-friendly biopharmaceutical company while improving environmental management by constantly improving internal management system and strictly managing environmental impacts.



and revised one Level-1 management manual, fourteen Level-2 procedural documents, and sixty-one Level-3

Energy Conservation Law of the People's Republic

Water Law of the People's Republic of

. We incorporate the efýcient utilization of water resources into production concept, formulate corresponding rules and regulations

pipel i-e

Nitrogen oxides(NOx) emissions			

Biopharmaceutical Industry Pollutant Discharge Standard (DB31/373-2010) *Comprehensive Wastewater Discharge Standard (DB31/199-2018)*

During the reporting period, the Company has continuously intensiýed the technical upgrade of wastewater treatment on the premise of ensuring that the wastewater meets the standard and optimized the

Chemical oxygen demand (COD)			
Ammonia nitrogen (NH3-N) emissions			

Standards for Pollution Control of Hazardous Waste Storage (GB18597-2023),

Collection, Storage and *Ë* *'*

	Ton/Litre		
	Ton/Litre		


*1: The calculation for domestic waste is optimized compared with previous years, the daily garbage generated in ofýce space is used as the unit for estimating annual domestic waste.



Company further updated and ᵠ ɔ ŭ̆ ɹ ɕ

Supply Chain Stability and Localization

resilience of supply chain in case of risk. To this end, the Company established supply chain Business Continuity Management (BCM) in 2023,




The Company gradually replaces imported materials with local materials through intensiýed industrial cooperath ٹ شہ hro ځ $ us â ! nagement


目录

Henlius is committed to giving back to the community, giving full play to our strengths to shoulder social responsibility. Henlius is always concerned about social needs, cooperates with all sectors of society, gives full play to its advantages in the industry, proposes "patient-centricity" concept, and carries out public welfare activities on the topic of "medical resources delivered to grassroots", "care for tumor patients" and "science popularization for the public". We also encourage employees to participate in these activities, and establish a volunteer platform named "Lanjinglin" for employees.


the Company continued to organize "To the Time, to Life" - Cancer Patient Care Program, "Standing Shoulder to Shoulder" - Breast Cancer Patient Care Public Welfare Program, "Care for Lung, Ride to Health " Charitable Cycling Activity, Rural Medical Service - Public



beneýting more than 4,700 patients and 2,200 primary medical staff,

Development Association (PhIRDA), and the ICH expert group of IFPMA (the International Federation of Pharmaceutical Manufacturers). The Company has participated in the China BioMed Innovation and Investment Conference (CBIIC) and BIO (BIO International Convention), CPhI Worldwide (Convention on Pharmaceutical Ingredients Worldwide), Chinese Congress of Holistic Integrative Oncology as well as other well-

Revised Working Procedures for Safety Information Assessment and Risk Management During Clinical Trials (Trial) (Draft for Comments)



Diversiýed Management

XINGLI WANG

Lik Yuen Chan


interim and annual ýnancial results, periodic reports, risk management and



the reporting period, the Remuneration Committee was convened ýve times







and ESG reports, conýrming the reasonableness of performance indicators and the accuracy of data, and reporting regularly to the Board. The ESG Committee consists of ýve members appointed by the Board from

responsibilities. The ESG Steering Group is responsible for formulating ESG-related targets, policies, speciýc

stakeholders so that material ESG issues can be identiýed and evaluated in a timely manner. Currently, the Company's identiýcation of material ESG issues is based on the materiality assessment by an independent third-party. The ýnal assessment results are formulated after discussion and approval by the ESG Committee

and enhance the eýciency of the ESG Steering Group and the ESG

Drug Administration Law of the

Implementation of the Drug Administration Law of
Advertising Law

Competition Law of the People's Republic of China,
Anti-Monopoly Law of the People's Republic of

Measures for the Management of Gifts and Premiums in Ofýcial
to clarify and reýne various prohibited behaviors

reports on important work carried out by the Audit Committee. Meanwhile, we continue to adhere to the ýve principles of handling violation incidents,

supervision departments, the audit department, the procurement department of Shanghai Fosun High Tech[illegible] of the HighHigh ï ý ‘A ᴴ the olw

Advertising Law of the People's Republic of China

and Interview Process Management Policy, Henlius Visual Identiýcation Handbook *WeChat Ofýcial Account Operation Administration*

to release relevant information in a timely, centralized and accurate manner through ofýcial channels including the _____ WeChat ofýcial account and press conferences to ensure consistency, promptness, accuracy and reasonableness of the information disclosure. No other persons except for the designated ofýcial spokespersons of the Company are permitted to accept media interviews or respond to enquiries from relevant

Laws and regulations related to responsible marketing, illegal reporting channels, compliance promotion and other items are strengthened. Precautions in

the ýrst week of employment, participate in online orientation within three months after employment and receive live training provided by the compliance team on the "Online Orientation Platform" to further clarify relevant compliance requirements. In addition, Henlius establishes "Knowledge Bird" platform

Henlius strictly abides by the laws and regulations in the regions where we operate, including the Law of the *Network Security Law*

annual audit of ISO/IEC 27001:2013 information security management system certiýcation.

t M

data encryption platform and strengthened AD


Patent Law of the People's Republic of China *Trademark Law of the People's Republic of China*
Copyright Law of the People's Republic of China

intellectual property professionals. During the reporting period, Henlius passed the annual third-party GB/T 29490-2013 audit (Code for the Management of Intellectual Property Rights of Enterprises).

property personnel will search and conduct due diligence on matters with intellectual property risks (such as supplier's products, services, etc.), and then offer consultation comments and recommendations, so as to


employees, such as signing the Declaration on IPR upon Enrolment, "intellectual property notiýcation" and approval of employee resignation. In addition, we have implemented classiýed protection of intellectual property rights, and carried out hierarchical management for patents, trademarks and other types of intellectual property rights in order to comprehensively improve the effectiveness of conýdentiality and management.

Ls k `cp md g l t c l rgm l n_rc l r _nnjga_rgm l q



In 2023, we participated in the "Asia Paciýc Biopharmaceutical Intellectual Property Innovation Summit 2023", focusing on the theme of "New Policy Environment Ł New IP Standards Ł New Opportunities for Cooperation", we actively offered advice and recommendations on biopharmaceutical policies, systems and hot issues, and held a round table discussion on the topic of "Patent Portfolio and Risk Aversion of Chinese Biopharmaceutical Enterprises in Europe" at the "Biopharmaceutical European Patent Strategy Seminar", which further improved our social inþuence and showcased our resolute commitments to safeguarding intellectual property rights.

Ls k `cp md g l t c l rgm l _l b srgjgrw k mbcj n_rc l rq ep_l rcb



arising from the Company's R&D process, Dr. Feng Li, a partner of Finnegan Law Firm in the United States, was invited to hold a lecture on "Patent Portfolio Strategy and Trade Secret Management" for the staff at the Shanghai

the Legal Department to discuss topics related to intellectual property rights

Henlius Applied for Shanghai Patent Navigation Project in Terms of Enterprise Management and R&D activities in 2023

was formally approved in May 2023. The project focused on the R&D activities of "anti-tumor antibody ð drug conjugates and their applications", carried out patent search and analysis, built ADC patent navigation database, and regularly updated competitive products and relevant technical patent information, and the analysis report of ADC subject patent FTO (Freedom To Operate).

Henlius was Awarded Shanghai Patent Work Demonstration Project for Enterprises and Institutions 2023

was ofýcially approved in September 2023. This was the second

the Intellectual Property Ofýce of Pudong New District based on

from three aspects of "improving working capabilities", "improving patent portfolio" and "building competitive advantages".


证 书

上海复宏汉霖生物技术股份有限公司

被评为上海市专利工作示范企业

上海市知识产权局

2023 年 9 月

证书编号：2023005A 企 05

有效期限：2023 年 11 月至 2025 年 10 月

Certiýcate of Shanghai Patent Work Demonstration Enterprise

Gasoline (self-owned vehicle gasoline consumption)	Litre
Power consumption (purchased power)	
	GJ/Litre
	Cubic meter /Litre

Chemical oxygen demand (COD) emissions
Ammonia nitrogen (NH3-N) emissions

Number of contractual employees (employees with disabilities)	
Number of rehired retirees (excluding labor outsourcing or labor dispatchers)	
Level	
Employee turnover rate by age: Less than 30 years old	

1. The calculation caliber in 2023 is the number of departures / (number of departures + total number of emm

The organization and its reporting practices

SGS Veriýcation Report

Activities and workers

Governance

Strategy, policies and practices

Stakeholder engagement

GRI 3: Material Topics 2021

List of material topics

Conýrmed incidents of corruption and actions taken

Legal actions foronrr c _ i w ˈ foro ɢ ɣ egali c ɖ i ɳ egal and Mand and

GRI 408: Child Labor 2016	
	Operations and suppliers at signiýcant risk for incidents of child labor
GRI 409: Forced or Compulsory Labor 2016	
	Operations and suppliers at signiýcant risk for incidents of forced or compulsory labor
GRI 417: Marketing and Labeling 2016	

?,Cl tgpml kclr_j

(a) the policies; and

(b) compliance with relevant laws and regulations that have a signiýcant impact on the issuer

Greenhouse gases include carbon dioxide, methane, nitrous oxide, hydroþuorocarbons, perþuorocarbons and sulphur hexaþuoride.

Hazardous wastes are those deýned by national regulations.

Direct (Scope 1) and energy indirect (Scope 2) greenhouse gas emissions (in tonnes) and, where appropriate, intensity (e.g. per unit of production volume, per facility).
Total hazardous waste produced (in tonnes) and, where appropriate, intensity (e.g. per unit of production volume, per facility).
Total non-hazardous waste produced (in tonnes) and, where appropriate, intensity (e.g. per unit of production volume, per facility).
Description of emission target(s) set and steps taken to achieve them.
Description of how hazardous and non-hazardous wastes are handled, and a description of reduction target(s) set and steps taken to achieve them.

Policies on the efýcient use of resources, including energy,

Direct and/or indirect energy consumption by type (e.g. electricity, gas or oil) in total (kWh in' 000s) and intensity (e.g. per unit of production volume, per facility).

:

	Policies on minimising the issuer's signiýcant impacts on the environment and natural resources.
	Description of the signiýcant impacts of activities on the environment and natural resources and the actions taken to manage them.
:	Policies on identiýcation and mitigation of signiýcant climate-related issues which have impacted, and those which may impact, the issuer.

Labour	(a) the policies; and the the

(a) the policies; and

(b) compliance with relevant laws and regulations that have a signiýcant impact on the issuer

/, g l ec l cp_j* r f c 0 . 01 Fc l jgsq CQE Pcnmpr gq8

Very good	Quite good	Somewhat good	Not so good	Not good at all

0, R f c bgqajmqspc md r f c 0 . 01 Fc l jgsq CQE Pcnmpr gq8

Very informative	Quite informative	Somewhat informative	Not so informative	Not informative at all

1, R f c os_jgrw md g l dmp k _rgm l bgqajmqcb g l r f c 0 . 01 Fc l jgsq CQE Pcnmpr gq8

Very high	Quite high	Somewhat good	Quite low	Very low

2, U f gaf md r f c dmjjm u g l e _pc_q g l r f c 0 . 02 Fc l jgsq CQE Pcnmpr l ccb rm `c qrpc l er f c l cb8

Idea elaboration	Data & charts	Case studies	Topics	Images

Veriýcation Report

Henlius

Shanghai Henlius Biotech, Inc.

www.henlius.com